Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%–timolol 0.5% therapy

References

• Choudhri S, Wand M, Shields MB. A comparison of dorzolamide–timolol combination versus the concomitant drugs. Am J Ophthalmol 2000;130:832–31Choudhri S, Wand M, Shields MB. A comparison of dorzolamide–timolol combination versus the concomitant drugs. Am J Ophthalmol 2000;130:832–3
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Craven ER, Chou C. et al. Twice-daily 0.2% brimonidine–0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230–82Sherwood MB, Craven ER, Chou C. et al. Twice-daily 0.2% brimonidine–0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230–8
   PubMed Web of Science ®Google Scholar
• Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999;127:20–63Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Am J Ophthalmol 1999;127:20–6
   PubMed Web of Science ®Google Scholar
• Arici MK, Sayici M, Toker M. et al. A short term study of the additive effect of timolol and brimonidine on intraocular pressure. Eye 2002;16:39–434Arici MK, Sayici M, Toker M. et al. A short term study of the additive effect of timolol and brimonidine on intraocular pressure. Eye 2002;16:39–43
   PubMed Web of Science ®Google Scholar
• Solish AM, DeLucca PT, Cassel DA. et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13:149–575Solish AM, DeLucca PT, Cassel DA. et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13:149–57
   PubMed Web of Science ®Google Scholar
• Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology 2002;109:307–146Simmons ST, Earl ML. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering. Ophthalmology 2002;109:307–14
   PubMed Web of Science ®Google Scholar
• Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581–907Goni FJ. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581–90
   PubMed Web of Science ®Google Scholar
• Alvarado JA. Reduced ocular allergy with fixed-combination 0.2% brimonidine–0.5% timolol. Arch Ophthalmol 2007; 125:717. [author reply 717-8]8Alvarado JA. Reduced ocular allergy with fixed-combination 0.2% brimonidine–0.5% timolol. Arch Ophthalmol 2007; 125:717. [author reply 717-8]
   PubMed Web of Science ®Google Scholar
• Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye 2004;18:24–69Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye 2004;18:24–6
   PubMed Web of Science ®Google Scholar
• Becker HI, Walton RC, Diamant JI. et al. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol 2004; 122:1063–610Becker HI, Walton RC, Diamant JI. et al. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol 2004; 122:1063–6
   PubMed Web of Science ®Google Scholar
• Hegde V, Robinson R, Dean F. et al. Drug-induced ectropion: what is best practice? Ophthalmology 2007; 114:362–611Hegde V, Robinson R, Dean F. et al. Drug-induced ectropion: what is best practice? Ophthalmology 2007; 114:362–6
   PubMed Web of Science ®Google Scholar
• Spaeth GL. Allergic contact dermatitis caused by topical eye drops. Am J Ophthalmol 2006;142:70612Spaeth GL. Allergic contact dermatitis caused by topical eye drops. Am J Ophthalmol 2006;142:706
   PubMed Web of Science ®Google Scholar
• Manni G, Centofanti M, Sacchetti M. et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma 2004;13: 163–713Manni G, Centofanti M, Sacchetti M. et al. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma 2004;13: 163–7
   PubMed Web of Science ®Google Scholar
• Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119–2614Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma 2002;11:119–26
   PubMed Web of Science ®Google Scholar
• Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther 2007;23:481–615Kim CY, Hong S, Seong GJ. Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension. J Ocul Pharmacol Ther 2007;23:481–6
   PubMed Web of Science ®Google Scholar
• Osborne SA, Montgomery DM, Morris D. et al. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye 2005;19:129–3716Osborne SA, Montgomery DM, Morris D. et al. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye 2005;19:129–37
   PubMed Web of Science ®Google Scholar
• Van Buskirk EM, Bacon DR, Fahrenbach WH. Ciliary vasoconstriction after topical adrenergic drugs. Am J Ophthalmol 1990; 109:511–717Van Buskirk EM, Bacon DR, Fahrenbach WH. Ciliary vasoconstriction after topical adrenergic drugs. Am J Ophthalmol 1990; 109:511–7
   PubMed Web of Science ®Google Scholar
• Butler P, Mannschreck M, Lin S. et al. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol 1995;113:293–618Butler P, Mannschreck M, Lin S. et al. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol 1995;113:293–6
   PubMed Web of Science ®Google Scholar